National Association for Proton Therapy establishes Physician Advisory Committee

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

To guide the National Association for Proton Therapy, the organization has created a Physician Advisory Committee.

The committee will advise NAPT on critical issues including advancing clinical research collaboration, patient education and equitable insurance reimbursement practices.

Chaired by J. Isabelle Choi, clinical director and research director of the New York Proton Center and Assistant Member at Memorial Sloan Kettering Cancer Center, the committee is comprised of national leaders in radiation oncology and proton therapy including:

  • Gopal Bajaj, Inova Schar Cancer Institute Proton Therapy Center,

  • Brian Baumann, S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center,

  • Jeff Bradley, Emory Proton Therapy Center,

  • Andrew Chang, California Protons Cancer Therapy Center,

  • Steve Frank, MD Anderson Cancer Center Proton Therapy Center,

  • James Gray, Provision CARES Proton Therapy Center,

  • Brandon Gunn, MD Anderson Cancer Center Proton Therapy Center,

  • Nancy Mendenhall, University of Florida Health Proton Therapy Institute,

  • Minesh Mehta, Miami Cancer Institute Proton Therapy Center at Baptist Health South Florida,

  • Charles Simone, New York Proton Center,

  • Christina Tsien, The Johns Hopkins National Proton Center,

  • Torunn Yock, Francis Burr Proton Therapy Center at Massachusetts General Hospital,

  • Jing Zeng, Seattle Cancer Care Alliance Proton Therapy Center.

Under Choi’s leadership, the NAPT Physician Advisory Committee will promote the benefits of proton therapy. The committee will attend advocacy meetings with federal and state government agencies and members of Congress, collaborate with other cancer-related stakeholders, and support proton therapy research.

Previously, Choi was an assistant professor at the University of Maryland School of Medicine and served as a clinical lead of the Maryland Proton Treatment Center.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login